GKIM
CYTK icon

GW&K Investment Management’s Cytokinetics CYTK Stock Holding History

GW&K Investment Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$32.6M Buy
494,619
+22,256
+5% +$1.41M 0.29% 127
2025
Q4 		$30M Buy
472,363
+291,693
+161% +$18.1M 0.26% 155
2025
Q3 		$9.93M Buy
+180,670
New +$7.44M 0.09% 251

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

GW&K Investment Management's CYTK Position: Q1 2026 in Review

GW&K Investment Management increased its Cytokinetics (CYTK) stake by 4.7% in Q1 2026, buying an estimated $1.41M and bringing the position to 494,619 shares worth $32.6M. The position accounts for 0.29% of the portfolio, ranked #127.

GW&K Investment Management first reported a position in CYTK in Q3 2025 and has held it in 3 quarters since. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • GW&K Investment Management held 494,619 shares of Cytokinetics worth $32.6M as of Q1 2026.
  • GW&K Investment Management bought 22,256 Cytokinetics shares in Q1 2026, an estimated $1.41M.
  • Cytokinetics made up 0.29% of GW&K Investment Management's portfolio in Q1 2026, its #127 holding.
  • GW&K Investment Management first reported a position in Cytokinetics in Q3 2025 and has held it in 3 quarters since.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on GW&K Investment Management's 13F filing for Q1 2026, filed 13 May 2026.